Blischak Matthew P. 4
4 · Finch Therapeutics Group, Inc. · Filed Jun 9, 2023
Insider Transaction Report
Form 4
Blischak Matthew P.
Chief Executive Officer
Transactions
- Award
Stock Option (right to buy)
2023-06-08+962,899→ 962,899 totalExercise: $0.28Exp: 2033-06-07→ Common Stock (962,899 underlying)
Footnotes (1)
- [F1]Twenty-five percent (25%) of the shares subject to this option shall vest on June 8, 2024, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service as of each such date.